drugset / Trial / NCT05402345
A Study of GlcNAc on Tear Production in NGLY1-CDDG
Phase 2
Active not recruiting
18 enrolled
Eva Morava-Kozicz
Children's Hospital of Philadelphia · collabSeattle Children's Hospital · collab
RandomizedParallel-groupTriple-blindTreatment
Summary
In patients with NGLY1-CDDG, the disorder can lead to eye damage due to not being able to produce enough tears. This study is being done to see if the dietary supplement, GlcNAc, improves tear production in patients with NGLY1-CDDG.
Timeline
- Start
- 2025-01-24
- Primary completion
- 2026-12
- Completion
- 2026-12
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | GlcNAc-GlcN | Unknown | — | Other |